Conventional systemic drug delivery often faces challenges such as poor aqueous solubility, rapid Elimination, non-specific toxicity, and an inability to traverse complex biological barriers. Over the last few decades, nanomedicine has profoundly transformed therapeutic Approaches by designing nanocarriers—including liposomes, polymeric nanoparticles, Micelles, dendrimers, and inorganic structures—that provide site-specific targeted delivery Along with controlled drug release profiles .Through tuning particle size, surface charge, and Surface functionalization (for instance, ligand attachment or PEGylation), these nanocarriers Shield therapeutic payloads from premature enzymatic breakdown, extend circulation Half-life, and enhance accumulation at target tissue sites via either passive Permeability or active cell-receptor targeting. This review brings together the fundamental mechanisms underlying nanoscale drug delivery, assesses emerging platforms—such as stimuli-responsive "smart" nanocarriers and Multimodal the ranostic agents—and emphasizes clinical achievements in oncology, Neurological disorders, and infectious diseases. Lastly, we examine key obstacles to Extensive clinical application, encompassing manufacturing scalability and consistency between batches. Reproducibility, sustained biocompatibility, and intricate regulatory structures. Closing These translational gaps will be crucial for unlocking the full potential of next-generation Personalized nanotherapeutics.
No takes yet. Share an insight, caveat, or question.
Barde et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: